Provided by Tiger Fintech (Singapore) Pte. Ltd.

Warrior Met Coal LLC

46.79
-0.2600-0.55%
Volume:798.23K
Turnover:37.19M
Market Cap:2.46B
PE:23.24
High:47.15
Open:46.03
Low:45.77
Close:47.05
Loading ...

Third Avenue Management Exits Lazard Inc, Impacting Portfolio by -2.99%

GuruFocus
·
14 Feb

Mohnish Pabrai's Strategic Move: Significant Increase in Warrior Met Coal Inc

GuruFocus.com
·
13 Feb

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
12 Feb

Warrior Met Coal Keeps Quarterly Dividend at $0.08 a Share, Payable March 3 to Holders of Record Feb. 24

MT Newswires Live
·
12 Feb

Warrior Announces Regular Quarterly Cash Dividend

Business Wire
·
12 Feb

Warrior Publishes 2024 Sustainability Report

Business Wire
·
11 Feb

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Business Wire
·
10 Feb

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

GlobeNewswire
·
10 Feb

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

GlobeNewswire
·
10 Feb

Those who invested in Warrior Met Coal (NYSE:HCC) five years ago are up 194%

Simply Wall St.
·
06 Feb

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

GlobeNewswire
·
05 Feb

Bank of New York Mellon and Fox Show Value and Momentum

GuruFocus.com
·
04 Feb

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

Zacks
·
04 Feb

Is Warrior Met Coal Inc. (HCC) the Best Coal Stock to Invest In Right Now?

Insider Monkey
·
31 Jan

4 Coal Stocks to Watch Despite Ongoing Industry Weakness

Zacks
·
30 Jan

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

GlobeNewswire
·
27 Jan

Warrior Sets Date for Fourth Quarter 2024 Earnings Announcement and Investor Conference Call

Business Wire
·
23 Jan

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

PR Newswire
·
22 Jan

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire
·
22 Jan

Is Warrior Met Coal (NYSE:HCC) Using Too Much Debt?

Simply Wall St.
·
18 Jan